Skip to main content
. 2006 Feb 16;103(9):3274–3279. doi: 10.1073/pnas.0511113103

Fig. 3.

Fig. 3.

Tpl2 is activated in BMDMs by diverse TLR ligands. Wild-type BMDMs were treated with TLR ligands for 30 min, lysed, and IP kinase assays were performed. Each bar represents the fold increase in Tpl2 activity versus normalized levels in untreated cells. Total amount of Tpl2 immunoprecipitated after each treatment was analyzed by Western blotting and used to normalize the kinase assay. This data are representative of independent experiments.